Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917879 | 0.88 | MEN1 (0.38) | ATMMEN1KMT2APOLBPARP1 | |
| SCHEMBL13091514 | 0.85 | ATM (0.35) | ATMMEN1KMT2ANR1H2POLB | |
| SCHEMBL2914416 | 0.85 | KMT2A (0.40) | ATMMEN1KMT2APOLB | |
| SCHEMBL2918069 | 0.82 | ATM (0.38) | ATMMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL2917328 | 0.74 | GHSR (0.36) | HDAC8POLBUSP30UCHL1 | |
| SCHEMBL30428673 | 0.73 | MTNR1B (0.43) | HDAC8 | |
| SCHEMBL13091501 | 0.72 | MEN1 (0.37) | ATMMEN1KMT2APARP1 | |
| SCHEMBL2909472 | 0.72 | NR1H2 (0.38) | ATMMEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL2984790 | 0.71 | MAPK1 (0.47) | NR1H2POLBUSP30 | |
| SCHEMBL3074912 | 0.70 | S1PR1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2220077-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | ATM 4682/4885MEN1 2317/4885KMT2A 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.